Osteoprotegerin in cardiometabolic disorders

International Journal of Endocrinology

Volumn 2015, Issue , 2015, Pages

  Perez De Ciriza C ^a   Lawrie, A ^b   Varo, N ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; AZELNIDIPINE; BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; INSULIN; METFORMIN; OLMESARTAN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PIOGLITAZONE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; ROSIGLITAZONE; SIMVASTATIN;

ATHEROSCLEROSIS; BARIATRIC SURGERY; CARDIOVASCULAR DISEASE; CORONARY ARTERY CALCIFICATION; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; WEIGHT LOSS PROGRAM;

EID: 84930679379     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2015/564934     Document Type: Review

References (121)

1. W. S. Simonet, D. L. Lacey, C. R. Dunstan et al., "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density", Cell, vol. 89, no. 2, pp. 309-319, 1997.
2. E. Tsuda, M. Goto, S.-I. Mochizuki et al., "Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis", Biochemical and Biophysical Research Communications, vol. 234, no. 1, pp. 137-142, 1997.
3. H. Yasuda, N. Shima, N. Nakagawa et al., "Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro", Endocrinology, vol. 139, no. 3, pp. 1329-1337, 1998.
4. S. M. Venuraju, A. Yerramasu, R. Corder, and A. Lahiri, "Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity", Journal of the American College of Cardiology, vol. 55, no. 19, pp. 2049-2061, 2010.
5. I. Silva and J. C. Branco, "Rank/RANKL/OPG: literature review", Acta Reumatologica Portuguesa, vol. 36, no. 3, pp. 209-218, 2011.
6. "Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption", Journal of Bone and Mineral Research, vol. 15, no. 12, pp. 2293-2296, 2000.
7. M. J. Hilton, L. Gutierrez, L. Zhang et al., "An integrated physical map of 8q22-q24: use in positional cloning and deletion analysis of Langer-Giedion syndrome", Genomics, vol. 71, no. 2, pp. 192-199, 2001.
8. M. Montagnana, G. Lippi, E. Danese, and G. C. Guidi, "The role of osteoprotegerin in cardiovascular disease", Annals of Medicine, vol. 45, no. 3, pp. 254-264, 2013.
9. S. Theoleyre, Y. Wittrant, S. K. Tat, Y. Fortun, F. Redini, and D. Heymann, "The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling", Cytokine and Growth Factor Reviews, vol. 15, no. 6, pp. 457-475, 2004.
10. K. Yamaguchi, "Characterization of structural domains of human osteoclastogenesis inhibitory factor", The Journal of Biological Chemistry, vol. 273, no. 9, pp. 5117-5123, 1998.
11. M. Baud'huin, L. Duplomb, S. Teletchea et al., "Osteoprotegerin: multiple partners for multiple functions", Cytokine and Growth Factor Reviews, vol. 24, no. 5, pp. 401-409, 2013.
12. H. L. Wright, H. S. McCarthy, J. Middleton, and M. J. Marshall, "RANK, RANKL and osteoprotegerin in bone biology and disease", Current Reviews in Musculoskeletal Medicine, vol. 2, no. 1, pp. 56-64, 2009.
13. B. F. Boyce and L. Xing, "Functions of RANKL/RANK/OPG in bone modeling and remodeling", Archives of Biochemistry and Biophysics, vol. 473, no. 2, pp. 139-146, 2008.
14. M. Schoppet, M. M. Kavurma, L. C. Hofbauer, and C. M. Shanahan, "Crystallizing nanoparticles derived from vascular smooth muscle cells contain the calcification inhibitor osteoprotegerin", Biochemical and Biophysical Research Communications, vol. 407, no. 1, pp. 103-107, 2011.
15. A. Lawrie, E. Waterman, M. Southwood et al., "Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension", American Journal of Pathology, vol. 172, no. 1, pp. 256-265, 2008.
16. A. C. W. Zannettino, C. A. Holding, P. Diamond et al., "Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor", Journal of Cellular Physiology, vol. 204, no. 2, pp. 714-723, 2005.
17. M.-E. Chollet, J.-P. Brouland, C. B. D. Sollier, F. Bauduer, L. Drouet, and S. Bellucci, "Evidence of a colocalisation of osteoprotegerin (OPG) with von Willebrand factor (VWF) in platelets and megakaryocytes alpha granules. Studies from normal and grey platelets", British Journal of Haematology, vol. 148, no. 5, pp. 805-807, 2010.
18. A. Bitto, G. De Caridi, F. Polito et al., "Evidence for markers of hypoxia and apoptosis in explanted human carotid atherosclerotic plaques", Journal of Vascular Surgery, vol. 52, no. 4, pp. 1015-1021, 2010.
19. C. Pérez de Ciriza, M. Moreno, P. Restituto et al., "Circulating osteoprotegerin is increased in the metabolic syndrome and associates with subclinical atherosclerosis and coronary arterial calcification", Clinical Biochemistry, vol. 47, no. 18, pp. 272-278, 2014.
20. A. C. Bharti, Y. Takada, S. Shishodia, and B. B. Aggarwal, "Evidence that receptor activator of Nuclear Factor (NF)-κB ligand can suppress cell Proliferation and induce apoptosis through activation of a NF-κB-independent and TRAF6-dependent mechanism", The Journal of Biological Chemistry, vol. 279, no. 7, pp. 6065-6076, 2004.
21. S. Khosla, "Minireview: the OPG/RANKL/RANK system", Endocrinology, vol. 142, no. 12, pp. 5050-5055, 2001.
22. K. Klejna, B. Naumnik, K. Gasowska, and M. Mýsliwiec, "OPG/RANK/RANKL signaling system and its significance in nephrology", Folia Histochemica et Cytobiologica, vol. 47, no. 2, pp. 199-206, 2009.
23. A. Van Campenhout and J. Golledge, "Osteoprotegerin, vascular calcification and atherosclerosis", Atherosclerosis, vol. 204, no. 2, pp. 321-329, 2009.
24. P. Reid and I. Holen, "Pathophysiological roles of osteoprotegerin (OPG)", European Journal of Cell Biology, vol. 88, no. 1, pp. 1-17, 2009.
25. D. Malliga, D. Wagner, and A. Fahrleitner-Pammer, "The role of osteoprotegerin (OPG) receptor activator for nuclear factor kappaB ligand (RANKL) in cardiovascular pathology-a review", Wiener Medizinische Wochenschrift, vol. 161, no. 23-24, pp. 565-570, 2011.
26. L. Nahidi, S. T. Leach, D. A. Lemberg, and A. S. Day, "Osteoprotegerin exerts its pro-inflammatory effects through nuclear factor-κb activation", Digestive Diseases and Sciences, vol. 58, no. 11, pp. 3144-3155, 2013.
27. M. Vaccarezza, R. Bortul, R. Fadda, and M. Zweyer, "Increased OPG expression and impaired opg/trail ratio in the Aorta of diabetic rats", Medicinal Chemistry, vol. 3, no. 4, pp. 387-391, 2007.
28. A. Augoulea, N. Vrachnis, I. Lambrinoudaki et al., "Osteoprotegerin as a marker of atherosclerosis in diabetic patients", International Journal of Endocrinology, vol. 2013, Article ID 182060, 6 pages, 2013.
29. G.-D. Xiang, H.-L. Sun, and L.-S. Zhao, "Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients", Diabetes Research and Clinical Practice, vol. 76, no. 2, pp. 199-206, 2007.
30. D. K. Singh, P. Winocour, B. Summerhayes, A. Viljoen, G. Sivakumar, and K. Farrington, "Low serum osteoprotegerin levels in normoalbuminuric type 1 diabetes mellitus", Acta Diabetologica, vol. 47, supplement 1, pp. S105-S110, 2010.
31. L. M. Rasmussen, L. Tarnow, T. K. Hansen, H.-H. Parving, and A. Flyvbjerg, "Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular mordibity in type 1 diabetic patients", European Journal of Endocrinology, vol. 154, no. 1, pp. 75-81, 2006.
32. J. Grauslund, L. M. Rasmussen, A. Green, and A. K. Sjølie, "Does osteoprotegerin relate to micro- and macrovascular complications in long-term type 1 diabetes?" Scandinavian Journal of Clinical & Laboratory Investigation, vol. 70, no. 3, pp. 188-193, 2010.
33. S. T. Wang, J. M. Xu, M. Wang, F. L. Chen, and G. Ding, "Increased plasma osteoprotegerin concentrations in Type 1 diabetes with albuminuria", Clinical Nephrology, vol. 79, pp. 192-198, 2013.
34. M. Nybo, M. K. Poulsen, J. Grauslund, J. E. Henriksen, and L. M. Rasmussen, "Plasma osteoprotegerin concentrations in peripheral sensory neuropathy in type 1 and type 2 diabetic patients", Diabetic Medicine, vol. 27, no. 3, pp. 289-294, 2010.
35. D. Gordin, A. Soro-Paavonen, M. C. Thomas et al., "Osteoprotegerin is an independent predictor of vascular events in finnish adults with type 1 diabetes", Diabetes Care, vol. 36, no. 7, pp. 1827-1833, 2013.
36. A. Jorsal, L. Tarnow, A. Flyvbjerg, H.-H. Parving, P. Rossing, and L. M. Rasmussen, "Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy", Diabetologia, vol. 51, no. 11, pp. 2100-2107, 2008.
37. A. Avignon, A. Sultan, C. Piot et al., "Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients", Diabetes Care, vol. 30, no. 11, pp. 2934-2939, 2007.
38. A. M. Blázquez-Medela, L. García-Ortiz, M. A. Gómez-Marcos et al., "Osteoprotegerin is associated with cardiovascular risk in hypertension and/or diabetes", European Journal of Clinical Investigation, vol. 42, no. 5, pp. 548-556, 2012.
39. A. Gaudio, F. Privitera, I. Pulvirenti, E. Canzonieri, R. Rapisarda, and C. E. Fiore, "Relationships between osteoprotegerin, receptor activator of the nuclear factor κB ligand and serum levels and carotid intima-media thickness in patients with type 2 diabetes mellitus", Panminerva Medica, vol. 56, pp. 221-225, 2014.
40. S. Guzel, A. Seven, A. Kocaoglu et al., "Osteoprotegerin, leptin and IL-6: association with silent myocardial ischemia in type 2 diabetes mellitus", Diabetes and Vascular Disease Research, vol. 10, no. 1, pp. 25-31, 2013.
41. S. Yaturu, J. Rains, and S. K. Jain, "Relationship of elevated osteoprotegerin with insulin resistance, CRP, and TNF-α levels in men with type 2 diabetes", Cytokine, vol. 44, no. 1, pp. 168-171, 2008.
42. E. P. O'Sullivan, D. T. Ashley, C. Davenport et al., "Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes", Diabetes/Metabolism Research and Reviews, vol. 26, no. 6, pp. 496-502, 2010.
43. Y.-H. Chang, K.-D. Lin, S.-R. He, M.-C. Hsieh, J.-Y. Hsiao, and S.-J. Shin, "Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy", Metabolism: Clinical and Experimental, vol. 60, no. 8, pp. 1064-1069, 2011.
44. H. M. Terekeci, M. G. Senol, C. Top et al., "Plasma osteoprotegerin concentrations in type 2 diabetic patients and its association with neuropathy", Experimental and Clinical Endocrinology and Diabetes, vol. 117, no. 3, pp. 119-123, 2009.
45. W. J. Y. Chen, L. J. Rijzewijk, R. W. van der Meer et al., "Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men", Cardiovascular Diabetology, vol. 10, article 67, 2011.
46. A. E. Altinova, F. Toruner, M. Akturk et al., "Relationship between serum osteoprotegerin, glycemic control, renal function and markers of atherosclerosis in type 2 diabetes", Scandinavian Journal of Clinical and Laboratory Investigation, vol. 71, no. 4, pp. 340-343, 2011.
47. S. Tavintharan, L. T. Pek, J. J. Liu et al., "Osteoprotegerin is independently associated with metabolic syndrome and microvascular complications in type 2 diabetes mellitus", Diabetes & Vascular Disease Research, vol. 11, no. 5, pp. 359-362, 2014.
48. S. T. Knudsen, C. H. Foss, P. L. Poulsen, N. H. Andersen, C. E. Mogensen, and L. M. Rasmussen, "Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications", European Journal of Endocrinology, vol. 149, no. 1, pp. 39-42, 2003.
49. G. Yu, X. Ji, J. Jin, and S. Bu, "Association of serum and vitreous concentrations of osteoprotegerin with diabetic retinopathy", Annals of Clinical Biochemistry, vol. 52, pp. 232-236, 2015.
50. M. Ishiyama, E. Suzuki, J. Katsuda et al., "Associations of coronary artery calcification and carotid intima-media thickness with plasma concentrations of vascular calcification inhibitors in type 2 diabetic patients", Diabetes Research and Clinical Practice, vol. 85, no. 2, pp. 189-196, 2009.
51. P. R. Moreno, R. R. García, A. García-Martin, M. Varsavsky, J. A. García-Salcedo, and M. Muñoz-Torres, "Serum osteoprotegerin: Bone or cardiovascular marker in type 2 diabetes males?" Journal of Endocrinological Investigation, vol. 36, no. 1, pp. 16-20, 2013.
52. A. Ndip, F. L. Wilkinson, E. B. Jude, A. J. Boulton, and M. Y. Alexander, "RANKL-OPG and RAGE modulation in vascular calcification and diabetes: novel targets for therapy", Diabetologia, vol. 57, no. 11, pp. 2251-2260, 2014.
53. A. Aoki, M. Murata, T. Asano et al., "Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes", Cardiovascular Diabetology, vol. 12, no. 1, article 11, 2013.
54. D. K. Singh, P. Winocour, B. Summerhayes et al., "Prevalence and progression of peripheral vascular calcification in type 2 diabetes subjects with preserved kidney function", Diabetes Research and Clinical Practice, vol. 97, no. 1, pp. 158-165, 2012.
55. D. V. Anand, A. Lahiri, E. Lim, D. Hopkins, and R. Corder, "The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects", Journal of the American College of Cardiology, vol. 47, no. 9, pp. 1850-1857, 2006.
56. D. V. Anand, E. Lim, D. Darko et al., "Determinants of progression of coronary artery calcification in type 2 diabetes: role of glycemic control and inflammatory/vascular calcification markers", Journal of the American College of Cardiology, vol. 50, no. 23, pp. 2218-2225, 2007.
57. O. Bourron, C. E. Aubert, S. Liabeuf et al., "Below-knee arterial calcification in type 2 diabetes: association with receptor activator of nuclear factor κB ligand, osteoprotegerin, and neuropathy", The Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 11, pp. 4250-4258, 2014.
58. H. Reinhard, M. Nybo, P. R. Hansen et al., "Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria", Cardiovascular Diabetology, vol. 10, article 70, 2011.
59. A. Avignon, A. Sultan, C. Piot, S. Elaerts, J. P. Cristol, and A. M. Dupuy, "Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients", Diabetes Care, vol. 28, no. 9, pp. 2176-2180, 2005.
60. M. K. Poulsen, M. Nybo, J. Dahl et al., "Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus", Cardiovascular Diabetology, vol. 10, article 76, 2011.
61. H. Reinhard, M. Lajer, M.-A. Gall et al., "Osteoprotegerin and mortality in type 2 diabetic patients", Diabetes Care, vol. 33, no. 12, pp. 2561-2566, 2010.
62. E. P. O'Sullivan, D. T. Ashley, C. Davenport et al., "A comparison of osteoprotegerin with adiponectin and high-sensitivity C-reactive protein (hsCRP) as a marker for insulin resistance", Metabolism: Clinical and Experimental, vol. 62, no. 1, pp. 34-38, 2013.
63. D. Hofsø, T. Ueland, H. Hager et al., "Inflammatory mediators in morbidly obese subjects: associations with glucose abnormalities and changes after oral glucose", European Journal of Endocrinology, vol. 161, no. 3, pp. 451-458, 2009.
64. S. T. Knudsen, P. Jeppesen, P. L. Poulsen et al., "Plasma concentrations of osteoprotegerin during normo- and hyperglycaemic clamping", Scandinavian Journal of Clinical and Laboratory Investigation, vol. 67, no. 2, pp. 135-142, 2007.
65. P. Secchiero, F. Corallini, A. Pandolfi et al., "An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction", American Journal of Pathology, vol. 169, no. 6, pp. 2236-2244, 2006.
66. G. M. Jorgensen, B. Vind, M. Nybo, L. M. Rasmussen, and K. Hojlund, "Acute hyperinsulinemia decreases plasma osteoprotegerin with diminished effect in type 2 diabetes and obesity", European Journal of Endocrinology, vol. 161, no. 1, pp. 95-101, 2009.
67. J. Suliburska, P. Bogdanski, E. Gajewska, G. Kalmus, M. Sobieska, and W. Samborski, "The association of insulin resistance with serum osteoprotegerin in obese adolescents", Journal of Physiology and Biochemistry, vol. 69, no. 4, pp. 847-853, 2013.
68. B. Ugur-Altun and A. Altun, "Circulating leptin and osteoprotegerin levels affect insulin resistance in healthy premenopausal obese women", Archives of Medical Research, vol. 38, no. 8, pp. 891-896, 2007.
69. D. T. Ashley, E. P. O'Sullivan, C. Davenport et al., "Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects", Metabolism: Clinical and Experimental, vol. 60, no. 7, pp. 994-1000, 2011.
70. B. Ugur-Altun, A. Altun, M. Gerenli, and A. Tugrul, "The relationship between insulin resistance assessed by HOMA-IR and serum osteoprotegerin levels in obesity", Diabetes Research and Clinical Practice, vol. 68, no. 3, pp. 217-222, 2005.
71. M. Holecki, B. Zahorska-Markiewicz, J. Janowska et al., "Osteoprotegerin-does it play a protective role in the pathogenesis of bone loss in obese perimenopausal women?" Endokrynologia Polska, vol. 58, no. 1, pp. 7-10, 2007.
72. A. A. Mahabadi, J. M. Massaro, G. A. Rosito et al., "Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study", European Heart Journal, vol. 30, no. 7, pp. 850-856, 2009.
73. M. C. Kühn, H. S. Willenberg, M. Schott et al., "Adipocytesecreted factors increase osteoblast proliferation and the OPG/RANKL ratio to influence osteoclast formation", Molecular and Cellular Endocrinology, vol. 349, no. 2, pp. 180-188, 2012.
74. P. Ducy, "The role of osteocalcin in the endocrine cross-talk between bone remodelling and energy metabolism", Diabetologia, vol. 54, no. 6, pp. 1291-1297, 2011.
75. V. Schwetz, T. Pieber, and B. Obermayer-Pietsch, "Mechanisms in endocrinology: the endocrine role of the skeleton: background and clinical evidence", European Journal of Endocrinology, vol. 166, pp. 959-967, 2012.
76. J. J. An, D. H. Han, D. M. Kim et al., "Expression and regulation of osteoprotegerin in adipose tissue", Yonsei Medical Journal, vol. 48, no. 5, pp. 765-772, 2007.
77. J. N. Fain, B. M. Tagele, P. Cheema, A. K. Madan, and D. S. Tichansky, "Release of 12 adipokines by adipose tissue, nonfat cells, and fat cells from obese women", Obesity, vol. 18, no. 5, pp. 890-896, 2010.
78. T. Harsløf, L. B. Husted, M. Carstens et al., "The expression and regulation of bone-acting cytokines in human peripheral adipose tissue in organ culture", Hormone and Metabolic Research, vol. 43, no. 7, pp. 477-482, 2011.
79. E. Fuentes, F. Fuentes, G. Vilahur, L. Badimon, and I. Palomo, "Mechanisms of chronic state of inflammation as mediators that link obese adipose tissue and metabolic syndrome", Mediators of Inflammation, vol. 2013, Article ID 136584, 11 pages, 2013.
80. B. Akinci, T. Demir, A. Celtik et al., "Serum osteoprotegerin is associated with carotid intima media thickness in women with previous gestational diabetes", Diabetes Research and Clinical Practice, vol. 82, no. 2, pp. 172-178, 2008.
81. B. Akinci, A. Celtik, F. Yuksel et al., "Increased osteoprotegerin levels in women with previous gestational diabetes developing metabolic syndrome", Diabetes Research and Clinical Practice, vol. 91, no. 1, pp. 26-31, 2011.
82. I. Nabipour, M. Kalantarhormozi, B. Larijani, M. Assadi, and Z. Sanjdideh, "Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women", Metabolism, vol. 59, no. 5, pp. 742-747, 2010.
83. D. Dallmeier, M. G. Larson, R. S. Vasan et al., "Metabolic syndrome and inflammatory biomarkers: a community-based cross-sectional study at the Framingham Heart Study", Diabetology and Metabolic Syndrome, vol. 4, article 28, 2012.
84. S. Bernardi, B. Fabris, M. Thomas et al., "Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes", Molecular and Cellular Endocrinology, vol. 394, no. 1-2, pp. 13-20, 2014.
85. E. Stępień, E. Wypasek, K. Stopyra, M. Konieczyńska, M. Przybylo, and M. Pasowicz, "Increased levels of bone remodeling biomarkers (osteoprotegerin and osteopontin) in hypertensive individuals", Clinical Biochemistry, vol. 44, no. 10-11, pp. 826-831, 2011.
86. E. Stpień, D. Fedak, P. Klimeczek et al., "Osteoprotegerin, but not osteopontin, as a potential predictor of vascular calcification in normotensive subjects", Hypertension Research, vol. 35, no. 5, pp. 531-538, 2012.
87. C. J. Lee, J. H. Wang, M. L. Chen, C. F. Yang, Y. C. Chen, and B. G. Hsu, "Serum osteoprotegerin is associated with arterial stiffness assessed according to the cardio-ankle vascular index in hypertensive patients", Journal of Atherosclerosis and Thrombosis, vol. 22, no. 3, pp. 304-312, 2015.
88. C. Guo, F. Hu, S. Zhang, Y. Wang, and H. Liu, "Association between osteoprotegerin gene polymorphisms and cardiovascular disease in type 2 diabetic patients", Genetics and Molecular Biology, vol. 36, no. 2, pp. 177-182, 2013.
89. S. MankočRamuš, T. Kumše, M. Globočnik Petrovič, D. Petrovič, and I. Cilenšek, "SNP rs2073618 of the psteoprotegerin gene is associated with diabetic retinopathy in Slovenian patients with type 2 diabetes", BioMed Research International, vol. 2013, Article ID 364073, 6 pages, 2013.
90. P. Nehring, B. Mrozikiewicz-Rakowska, A. Sobczyk-Kopciol et al., "Osteoprotegerin gene rs2073617 and rs3134069 polymorphisms in type 2 diabetes patients and sex-specific rs2073618 polymorphism as a risk factor for diabetic foot", Polskie Archiwum Medycyny Wewnetrznej, vol. 123, no. 4, pp. 176-182, 2013.
91. J. Golledge, E. Biros, P. Clancy, M. Cooper, L. J. Palmer, and P. E. Norman, "A single-nucleotide polymorphism in the gene encoding osteoprotegerin is associated with diastolic blood pressure in older men", American Journal of Hypertension, vol. 22, no. 11, pp. 1167-1170, 2009.
92. H. Brändström, P. Gerdhem, F. Stiger et al., "Single nucleotide polymorphisms in the human gene for osteoprotegerin are not related to bone mineral density or fracture in elderly women", Calcified Tissue International, vol. 74, no. 1, pp. 18-24, 2004.
93. H. Brändström, F. Stiger, T. Kahan et al., "A single nucleotide polymorphism in the promoter region of the osteoprotegerin gene is related to intima-media thickness of the carotid artery in hypertensive patients. The Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA)", Blood Pressure, vol. 13, no. 3, pp. 152-157, 2004.
94. G.-D. Xiang, L. Xu, L.-S. Zhao, L. Yue, and J. Hou, "The relationship between plasma osteoprotegerin and endotheliumdependent arterial dilation in type 2 diabetes", Diabetes, vol. 55, no. 7, pp. 2126-2131, 2006.
95. J. S. Park, M. H. Cho, J. S. Nam et al., "Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus", European Journal of Endocrinology, vol. 164, no. 1, pp. 69-74, 2011.
96. M. Nybo, S. R. Preil, H. F. Juhl et al., "Rosiglitazone decreases plasma levels of osteoprotegerin in a randomized clinical trial with type 2 diabetes patients", Basic and Clinical Pharmacology and Toxicology, vol. 109, no. 6, pp. 481-485, 2011.
97. B. Nellemann, L. C. Gormsen, J. Dollerup et al., "Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria", Diabetes Care, vol. 30, no. 12, pp. 3122-3124, 2007.
98. K. Mori, S. Jono, M. Emoto et al., "Effects of pravastatin on serum osteoprotegerin levels in patients with hypercholesterolemia and type 2 diabetes", Angiology, vol. 61, no. 1, pp. 86-91, 2010.
99. N. Nezami, J. Safa, A. T. Eftekhar-Sadat et al., "Lovastatin raises serum osteoprotegerin level in people with type 2 diabetic nephropathy", Clinical Biochemistry, vol. 43, no. 16-17, pp. 1294-1299, 2010.
100. N. P. E. Kadoglou, G. Kottas, S. Lampropoulos, I. Vitta, and C. D. Liapis, "Serum levels of fetuin-A, osteoprotegerin and osteopontin in patients with coronary artery disease: effects of statin (HMGCoA-reductase inhibitor) therapy", Clinical Drug Investigation, vol. 34, no. 3, pp. 165-171, 2014.
101. P. P. Dimitrow, M. Jawień, and A. Gackowski, "The influence of statins on levels of calcification biomarkers in patients with aortic sclerosis or mild aortic stenosis", Journal of Heart Valve Disease, vol. 20, no. 1, pp. 18-22, 2011.
102. H. Uzui, T. Morishita, A. Nakano et al., "Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension", Journal of Cardiovascular Pharmacology and Therapeutics, vol. 19, no. 3, pp. 304-309, 2014.
103. M. Holecki, B. Zahorska-Markiewicz, J. Janowska et al., "The influence of weight loss on serum osteoprotegerin concentration in obese perimenopausal women", Obesity, vol. 15, no. 8, pp. 1925-1929, 2007.
104. M.-H. Gannagé-Yared, C. Yaghi, B. Habre et al., "Osteopro - tegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study", European Journal of Endocrinology, vol. 158, no. 3, pp. 353-359, 2008.
105. C. Davenport, H. Kenny, D. T. Ashley, E. P. O'Sullivan, D. Smith, and D. J. O'Gorman, "The effect of exercise on osteoprotegerin and TNF-related apoptosis-inducing ligand in obese patients", European Journal of Clinical Investigation, vol. 42, no. 11, pp. 1173-1179, 2012.
106. P. Collin-Osdoby, L. Rothe, F. Anderson, M. Nelson, W. Maloney, and P. Osdoby, "Receptor activator of NF-κb and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis", Journal of Biological Chemistry, vol. 276, no. 23, pp. 20659-20672, 2001.
107. J. S. McGonigle, C. M. Giachelli, and M. Scatena, "Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function", Angiogenesis, vol. 12, no. 1, pp. 35-46, 2009.
108. S. H. Mangan, A. van Campenhout, C. Rush, and J. Golledge, "Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-α associated with induction of angiopoietin-2", Cardiovascular Research, vol. 76, no. 3, pp. 494-505, 2007.
109. G. Zauli, F. Corallini, F. Bossi et al., "Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo", Blood, vol. 110, no. 2, pp. 536-543, 2007.
110. M.-F. Heymann, F. Herisson, J.-M. Davaine et al., "Role of the OPG/RANK/RANKL triad in calcifications of the atheromatous plaques: comparison between carotid and femoral beds", Cytokine, vol. 58, no. 2, pp. 300-306, 2012.
111. B. Toffoli, R. J. Pickering, D. Tsorotes et al., "Osteoprotegerin promotes vascular fibrosis via a TGF-β1 autocrine loop", Atherosclerosis, vol. 218, no. 1, pp. 61-68, 2011.
112. A. Callegari, M. L. Coons, J. L. Ricks, M. E. Rosenfeld, and M. Scatena, "Increased calcification in osteoprotegerin-deficient smooth muscle cells: dependence on receptor activator of NF-κB Ligand and Interleukin 6", Journal of Vascular Research, vol. 51, no. 2, pp. 118-131, 2014.
113. R. Candido, B. Toffoli, F. Corallini et al., "Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo", Journal of Vascular Research, vol. 47, no. 3, pp. 252-261, 2010.
114. (-/-) mice", Circulation, vol. 117, no. 3, pp. 411-420, 2008.
115. K. Caidahl, T. Ueland, and P. Aukrust, "Osteoprotegerin: a biomarker with many faces", Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 9, pp. 1684-1686, 2010.
116. P. Clancy, L. Oliver, R. Jayalath, P. Buttner, and J. Golledge, "Assessment of a serum assay for quantification of abdominal aortic calcification", Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 11, pp. 2574-2576, 2006.
117. K. E. Naylor, A. Rogers, R. B. Fraser, V. Hall, R. Eastell, and A. Blumsohn, "Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation", Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 11, pp. 5361-5365, 2003.
118. C. Pérez de Ciriza, A. Lawrie, and N. Varo, "Influence of preanalytical and analytical factors on osteoprotegerin measurements", Clinical Biochemistry, vol. 47, no. 13-14, pp. 1279-1285, 2014.
119. B. Y. Y. Chan, K. A. Buckley, B. H. Durham, J. A. Gallagher, and W. D. Fraser, "Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-κB ligand and osteoprotegerin in plasma and serum", Clinical Chemistry, vol. 49, no. 12, pp. 2083-2085, 2003.
120. M. Bjerre, "Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications", SpringerPlus, vol. 2, article 658, 2013.
121. H. P. Sennels, S. Jacobsen, T. Jensen et al., "Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high-sensitivity C-reactive protein", Scandinavian Journal of Clinical & Laboratory Investigation, vol. 67, no. 8, pp. 821-835, 2007.